TABLE X.A.4-4.
Evidence for omalizumab for the treatment of asthma in the context of coexistent allergic rhinitis
Study | Year | LOE | Study design | Study groups | Clinical endpoint | Conclusion |
---|---|---|---|---|---|---|
Kopp et al.1403 | 2009 | 1b | DBRCT | AR and seasonal asthma. All patients received SCIT. (n = 140):
|
AR and asthma symptoms, rescue medication use, PEF, patient and provider GETE, asthma symptoms by ACQ, disease-specific QOL by AQLQ and RQLQ, PFTs | Omalizumab addition to SCIT: reduced symptom severity, improved QOL by ACQ and AQLQ. No difference in rescue medication use. No difference in FEV1 or mean PEF. |
Vignola et al.1820 | 2004 | 1b | DBRCT | Moderate-to-severe persistent AR and allergic asthma (n = 405):
|
Asthma exacerbations, disease-specific QOL by AQLQ and RQLQ, rescue medication use, symptom scores, patient and investigator GETE, inhaled corticosteroid use, FEV1, FVC, and morning PEF | Omalizumab: reduced asthma exacerbations; increased AQLQ and RQLQ; reduced asthma symptoms; increased FEV1, FVC, and PEF. No difference in β-agonist use. |
ACQ = Asthma Control Questionnaire; AQLQ = Asthma Quality of Life Questionnaire; AR = allergic rhinitis; DBRCT = double-blind randomized controlled trial; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; GETE = Global Evaluation of Treatment Effectiveness; LOE = level of evidence; PEF = peak expiratory flow; PFT = pulmonary function test; QOL = quality of life; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SCIT = subcutaneous immunotherapy.